Skip to main content

Advertisement

  • Research Article
  • Open Access

Synthesis and antitumor activities of 3-substituted-analine derivatives: structure modifications of Tuv part of tubulysins

Chemistry Central Journal201812:115

https://doi.org/10.1186/s13065-018-0483-5

©  The Author(s) 2018

  • Received: 4 July 2017
  • Accepted: 3 November 2018
  • Published:

Abstract

Background

Tubulysins family is a kind of natural compound with potent, antitumor activity. To simplify the synthesis route and find new antitumor compounds is becoming a hotspot of research recent years.

Results

Starting from 3-nitrobenzoic acid, after 7 steps transformations, 12 new tubulysin analogues were synthesized by the conformational restraint and bioisostere principle. These structures are featuring 3-substituted analine moieties. All these compounds are new compounds, and the structures were characterized by 1H NMR, 13C NMR, and HRMS. The antitumor activities were screened by the MTT method using MDA-MB-231and MCF7 cells.

Conclusions

Compound IIb exhibited certain antitumor activity with the IC50 value of 7.6 and 11.8 µM against MDA-MB-231 and MCF7 cells respectively. Compounds IIa–IIe had moderate antitumor activities suggested that the thiazole ring in the Tuv could be replaced by the phenyl ring. However, Compounds Ia–Ie lose antitumor activity dramatically suggested that the conformation of the Tuv was crucial for the tubulysin analogues to maintain the biological activity.

Keywords

  • Tubulysin
  • Analogues
  • Synthesis
  • Antitumor activity

Background

Tubulysins (Fig. 1) are natural tetrapeptides isolated by Höfle in 2001 [1]. They possess potent antitumor activities by binding to tubulin near the vinca alkaloid binding site and inhibiting tubulin polymerization [1]. The average IC50 against mammalian cancer cells ranged from 0.01 to 10 nM [2]. Due to the high potency and limited availability, there have been several total synthesis routes reported ever since the first total synthesis of tubulysin D by Ellman’s group [3–5]. In 2009, Pretubulysin (Fig. 1), the precursor to tubulysin, was found by Müller from Angiococcus disciformis [6]. Although it was less potent than the tubulysin, the anticancer activities still retained subnanomolar level [7–9]. The extraordinary anticancer activity of tubulysin and pretubulysin against a validated target makes them exciting leads for the development of novel drugs for multidrug-resistant cancers.
Fig. 1
Fig. 1

Structures of tubulysins and pretubulysin

Results and discussion

Chemistry

Some issues, such as less lipophilicity, large molecular weight ( > 700) and too many stereocenters, have hampered tubulysin from becoming a commercial drug. In our lab, efforts were taken to modify the structure of tubulysin in order to increase the lipophilicity and decrease the numbers of stereocenters. In all the total synthesis routes of tubulysin, one of the biggest challenges was to build the Tuv part. Utilizing conformational restrain principle, a new series of tubulysin analogues were designed by cyclization and aromatization of the i-propyl group and R2 group into a phenyl ring (Scheme 1). Some advantages, like decreasing numbers of stereocenters, increasing lipophilicity, and simplifying the synthesis, were obvious to this series of compounds.
Scheme1
Scheme1

Synthesis of tubulysins derivatives Ia–Ie

Starting from commercially available ethyl 2-aryl-4-thiazole-carboxylate (1), after three steps transformation, compound 3 was obtained. The l-phenylalanine was chosen instead of the Tup in the tubulysin, because a previous structure–activity-relationship study showed that the Tup had little effect on the antitumor activity [10, 11]. After two classical peptide coupling reactions and one hydrolysis reaction, compound Ia–Ie were obtained in moderate yields. To fulfill our design, l-leucine and benzoic acids were used in the peptide coupling. Compared with tubulysins, this series of compounds were relatively low molecular weight (around 550), and less stereocenters (Scheme 1).
Scheme2
Scheme2

Synthesis of tubulysin derivatives IIa–IIg

Inspired by the structure of pretubulysin, compounds IIa–IIg (Scheme 2) were designed and synthesized. In these compounds, peptide bonds were adopted as the linker to connect the Tuv and Tup parts, instead of the ethylene group in pretubulysin. Besides the thiazole group, a phenyl group was also used according to the bioisosterism principle. Another reason that a phenyl group was used was because there were at most 4 positions could be utilized to introduce substituents to modify the pharmacokinetic profiles of the compounds.

The syntheses of compounds IIa–IIg started from 3-nitrobenzoic acid or 2-bromo-5-nitro-benzoic acid. After the amide bond formation reaction and hydrogenation reaction, compound 4 was obtained and used in the next step to couple with Boc-l-Val directly to obtain compound 5. Then, by classical peptide coupling conditions, the Leu part and N-Mep part were installed subsequently utilizing classical peptide coupling reaction.

Antitumor activity

Human cancer cell lines Siha, PC3 and MKN45 were cultured in RPMI-1640 media supplemented with 10% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) (Gibco BRL, NY, USA), and incubated at 37 °C in a humidified air atmosphere containing 5% CO2. All cells were harvested in their exponentially growing phase.

Cell viability was measured using (MTT) assay. Briefly, Cells were seeded in 96-well multi-plates at a density of 4 × 104/mL. After incubated overnight, triplicate wells were exposed to vehicle and test agents for 72 h. MTT solution (5 mg/mL) was added to each well and incubated continued for 4 h. DMSO was added to dissolve the MTT formazan product and the absorbance was measured at 570 nm using a Molecular Devices SpectraMax M5 (Molecular Devices, USA). The relative cell viability rates were calculated versus untreated controls. The 50% inhibitory concentration (IC50) values were calculated using the Graph Pad Prism 5 (Graph Pad Software, Inc., USA). The antitumor activities of all the synthesized compounds were listed in Table 1.
Table 1

The antitumor activities of the compounds Ia–IIg

Compd.

IC50 (μm)

Compd.

IC50 (μm)

MDA-MB-231

MCF7

MDA-MB-231

MCF7

Ia

> 20

> 20

IIa

17.1

> 20

Ib

> 20

> 20

IIb

7.6

11.8

Ic

> 20

> 20

IIc

16.3

> 20

Id

> 20

> 20

IId

> 20

15.5

Ie

> 20

> 20

IIe

16.3

> 20

Taxol

< 0.01

0.006

IIf

> 20

> 20

   

IIg

> 20

> 20

The antitumor activities of compound Ia–Ie were not as expected, while compounds IIa–IIe had moderate antitumor activities. This suggests that the conformation of the Tuv and Tup parts was crucial to the antitumor activity. In compounds Ia–Ie, due to the conformational restraint,the Tuv part and Tup part were co-planar and separated far apart, which led to weak or no interaction with tublin. However, in tubulysins and compounds IIa–IIe, the ethylene or amide bond linker can freely rotate, which results in the Tuv and Tup parts binding better with tublin. This observation was consistent with previously reported results of THP-tubulysins [12, 13]. On the other hand, Tamura [14] reported that cyclotubulysin, an analog with a N,O-acetal ring generated from C-11 alcohol and N-14, had a similar antitumor activity with vinblastine. This also suggests that the conformation of Tuv and Tup part was crucial to the antitumor activity. Previous SAR studies showed that the entire Tup residue was not essential for activity [10]. In order to simply the synthesis, l-Phe was arbitrarily selected in this study. However, according to Ullrich’s findings [15], compounds IIa–IIe would increase the activities by replacement of l-Phe with Tup. The reason why compound IIf and IIg had no activities is not clear yet. Although more work is needed to increase the potency, this work shows at the very least that the phenyl ring could be used to replace the thiozole ring of the Tuv.

Conclusions

Compound IIb exhibited certain antitumor activity with the IC50 value of 7.6 and 11.8 µM against MDA-MB-231 and MCF7 cells respectively. Compounds IIa–IIe had moderate antitumor activities suggested that the thiazole ring in the Tuv could be replaced by the phenyl ring. However, Compounds Ia–Ie lose antitumor activity dramatically suggested that the conformation of the Tuv was crucial for the tubulysin analogues to maintain the biological activity.

Experimental section

Chemistry

Reactions employed oven- or flame-dried glassware under nitrogen unless otherwise noted. Thin layer chromatography (TLC) employed glass 0.25 mm silica gel plates with UV indicator. Flash chromatography columns were packed with 230–400 mesh silica gel as a slurry in the initial elution solvent. Gradient flash chromatography was conducted by adsorption of product mixtures on silica gel, packing over a short pad of clean silica gel as a slurry in hexane, and eluting with a continuous gradient as indicated. Nuclear magnetic resonance (NMR) data were obtained at operating frequencies indicated in the text and are reported in units of ppm. Infrared spectra were recorded using a single beam FT-IR spectrophotometer by standard transmission method. Low and high resolution mass spectra (TOF) were obtained from local instrumentation facilities services.

(S)-Ethyl 2-(2- (3-amiophenyl)thiazole-4-carboxamido)-3-phenylpropanoate (2)

Step 1: To a solution of compound 1 (5.56 g, 20 mmol) in 60 mL THF:H2O (1:1), was added NaOH aqueous solution (2.40 g, 60 mmol) at room temperature. The reaction mixture was allowed to stir at room temperature for 10 h till TLC showed that starting material all consumed. The solvent was removed by vaccum, the residue was adjusted the pH to 2 by 10% HCl. The white precipitate was isolated and washed with water, dried and used in next step with further purification. Step 2: The solid obtained in last step was dissolved in 100 mL DCM, SOCl2 (4.5 mL, 60 mmol) and 0.5 mL DMF was added at room temperature. The reaction mixture was allowed to stir at reflux condition for 4 h. The excess SOCl2 and DCM were removed under reduced pressure. The residue was diluted with 50 mL DCM and added through an additional funnel to a solution of l-Phe-OEt (3.86 g, 20 mmol) , Et3N (6.06 g, 60 mmol) in 100 mL DCM at 0 degree. The reaction mixture was allowed to stir at 0 degree for 30 min, then room temperature for 1 h. Water was added the reaction mixture, the aqueous layer was extracted with DCM (100 mL × 3). The organic layers were combined and dried over Na2SO4. The solvent was filtered, concentrated to afford pale yellow oil, which afforded a white solid after recrystallization from a co-solvent of EA/methanol. Yield: 87%.1H NMR (400 MHz, CDCl3) δ: 8.79 (t, J = 1.9, 1H), 8.34 (ddd, J = 8.2, 2.2, 0.9, 1H), 8.29–8.22 (m, 1H), 8.20 (s, 1H), 7.84 (d, J = 8.2, 1H), 7.69 (t, J = 8.0, 1H), 7.40–7.34 (m, 2H), 7.34–7.30 (m, 1H), 7.27–7.23 (m, 2H), 5.07 (dt, J = 8.2, 6.1, 1H), 4.23 (q, J = 7.1, 2H), 3.38–3.22 (m, 2H), 1.28 (t, J = 7.1, 3H). Step3. The above solid 7.40 g (17.4 mmol) was dissolved in MeOH,then about 0.5 g Pd/C (10%) was added. The reaction mixture was allowed to stir at 35 °C for 7 h under H2 (0.3 MPa) condition. After the reaction completed, the catalyst was removed by passing through a pad of celit, the filtrate was concentrated, and the residue (6.87 g brown solid) was used in next step directly.

(S)-Ethyl 2-(2-(3-((S)-2-((tert-butoxycarbonyl)amino)-4-methylpentanamido)phenyl)thiazole-4-carboxamido)-3-phenylpropanoate (3)

To a solution of Boc-l-Leu (4.02 g, 17.4 mmol) dissolved in 40 mL DCM,was added EDC (5.01 g, 26.1 mmol), HOBt (2.35 g, 17.4 mmol), and 1 mL DIPEA at room temperature. The reaction mixture was allowed to stir at room temperature for 1 h,then a solution of compound 4 (6.87 g, 17.4 mmol) in 20 mL DCM was added dropwisely. The reaction mixture stirred for 12 h at room temperature. Water 100 mL was added to the reaction mixture and the aqueous layer was extracted with DCM (100 mL × 3). The organic layers were combined, dried with Na2SO4, filtered and concentrated. The residue (pale yellow oil 10 g) was purified by chromatography (EA: PE = 1:4) to afford white solid 8.46 g, yield: 80%. 1H NMR (400 MHz, CDCl3) δ: 9.44 (s, 1H), 8.49 (d, J = 7.6, 1H), 7.92 (s, 1H), 7.84 (s, 1H), 7.74 (d, J = 7.8, 1H,), 7.36 (d, J = 7.3, 1H), 7.29 (s, 2H), 7.26 -7.21 (m, 1H), 7.18 (d, J = 7.6, 1H), 5.75 (s, 1H), 5.17 (dd, J = 15.0, 7.2, 1H), 4.53 (s, 1H), 4.23 (q, J = 7.1, 2H), 3.41–3.22 (m, 2H), 2.02 (d, J = 15.8, 1H), 1.82 (ddd, J = 25.6, 13.7, 7.0, 3H), 1.46–1.36 (m, 9H), 1.26 (t, J = 7.1, 4H), 1.03 (dd, J = 13.3, 6.3, 6H).

General synthesis method for compound Ia–Ie

Step 1: To a solution of D-N-Methyl-2-pipecolinic acid (0.04 g, 0.26 mmol) in 4 mL DCM,was added EDC (0.08 g, 0.39 mmol), HOBt (0.04 g, 0.26 mmol), 0.5 mL DIPEA at 0 °C. The reaction mixture was stirred for 1 h at room temperature. Meanwhile, a solution of compound 3 (0.16 g, 0.26 mmol) in 4 mL TFA was allowed to stir at room temperature for 3 h. The excess TFA was removed under reduced pressure, the residue was dissolved in 5 mL DCM and0.5 mL DIPEA. This solution was added to above reaction mixture under 20 °C. The reaction mixture was allowed to stir overnight at room temperature. Water 50 mL was added to reaction mixture, the aqueous layer was extracted with DCM (40 mL × 3). The organic layers were combined, dried with Na2SO4, filtered and concentrated. The residue was purified by chromatography (EA:PE = 1:4) to afford white solid 0.13 g, yield: 81%.

Step 2: To a solution of above solid 0.11 g (0.17 mmol) in THF:H2O = 1:1 (10 mL, v:v), was added LiOH (0.02 g, 0.83 mmol). The reaction mixture was allowed to stir at room temperature till TLC showed that all starting material consumed. Solvent was removed under reduced pressure, the residue was diluted with water 50 mL, and adjusted with 10% HCl to pH = 2, extracted with DCM (40 mL × 3). The organic layers were combined, dried with Na2SO4, filtered and concentrated. The residue was purified by chromatography (Chloroform: MeOH = 7: 1) to afford white solid 80 mg, yield: 77%. 1H NMR (CD3OD, 400 MHz) δ: 8.19 (s, 1H), 8.07 (s, 1H), 7.61 (dd, J = 16.0, 8.0, 2H), 7.35 (t, J = 7.9, 1H), 7.16 (dd, J = 17.6, 7.2, 4H), 7.08 (t, J = 6.8, 1H), 4.66–4.59 (m, 1H), 4.45 (dd, J = 9.8, 4.6, 1H), 3.30–3.25 (m, 1H), 2.97 (m, 1H), 2.69 (s, 3H), 1.83 (m, 3H), 1.66 (m, 6H), 1.51 (d, J = 12.5, 2H), 1.33–1.14 (m, 1H), 0.91 (dd, J = 10.8, 6.1, 6H); HRMS calcd for C32H39N5O5S [M+H]+ 606.2750, found 606.2755.

Ib: white solid, yield: 80%.1H NMR (CD3OD, 400 MHz) δ: 8.29 (s, 1H), 8.16 (d, J = 2.5, 1H), 7.71 (d, J = 6.6, 1H), 7.64 (t, J = 7.3, 1H), 7.44 (t, J = 7.9, 1H), 7.31–7.22 (m, 4H), 7.19 (d, J = 6.5, 1H), 4.63 (m, 1H), 4.45 (dd, J = 9.8, 4.6, 1H), 3.30–3.25 (m, 1H), 2.97 (m, 1H), 2.69 (s, 3H), 1.83 (m, 3H), 1.66 (m, 6H), 1.51 (d, J = 12.5, 2H), 1.33–1.14 (m, 1H), 0.91 (dd, J = 10.8, 6.1, 6H); 13C NMR (CD3OD, 100 MHz) δ: 20.3, 22.0, 24.7, 29.6, 37.9, 40.5, 42.8, 52.6, 54.3, 55.2, 55.9, 68.4, 115.3, 117.5, 118.2, 121.8, 123.2, 126.1, 127.8, 129.3, 133.2, 137.7, 139.1, 150.2, 161.0, 161.4, 161.7, 167.9, 171.9; HRMS calcd for C32H39N5O5S [M+H]+ 606.2750, found 606.2755.

Ic: white solid, yield: 79%.1H NMR (CD3OD, 400 MHz) δ: 8.23 (d, J = 1.7, 1H), 8.09 (s, 1H), 7.65 (d, J = 7.7, 1H), 7.59 (dd, J = 8.2, 1.1, 1H), 7.36 (t, J = 8.0, 1H), 7.18 (d, J = 4.4, 4H), 7.11 (m, 1H), 4.58–4.45 (m, 1H), 3.93 (q, J = 15.6, 1H), 3.34–3.23 (m, 1H), 3.12 (m, 1H), 2.84 (s, 6H), 1.62 (m, 3H), 1.24–1.16 (m, 2H), 0.92 (t, J = 6.2, 6H);13C NMR (CD3OD, 100 MHz) δ: 20.4, 22.0, 24.6, 36.9, 40.6, 43.0, 52.9, 57.8, 117.5, 121.9, 122.1, 123.7, 126.4, 128.1, 129.1, 132.9, 136.6, 138.9, 149.7, 161.2, 164.5, 168.1, 171.8; HRMS calcd for C29H35N5O5S [M+H]+ 566.2437, found 566.2434.

Id: white solid, yield: 75%. 1H NMR (CD3OD, 400 MHz) δ: 8.25 (s, 1H), 8.06 (s, 1H), 7.84–7.86 (m, 2H), 7.58–7.62 (m, 1H), 7.42–7.47 (m, 1H), 7.31–7.35 (m, 4H), 7.16–7.18 (m, 2H), 6.97–7.08 (m, 1H), 6.95–6.97 (m, 2H), 4.74–4.78 (m, 2H), 3.11–3.2 (m, 1H), 1.69–1.74 (m, 3H), 0.94–0.96 (d, J = 6.2, 6H), 0.78–0.80 (m, 1H);13C NMR (CD3OD, 100 MHz) δ: 20.9, 22.2, 36.9, 41.3, 50.9, 53.1, 117.7, 120.7, 121.0, 121.9, 122.0, 123.7, 126.5, 128.1, 129.0, 129.4, 130.8, 133.1, 136.6, 139.0, 139.6, 149.6, 161.7, 166.4, 168.1, 172.2, 174.9; HRMS calcd for C32H32N4O5S [M+H]+ 585.2093, found 585.2104.

Ie: white solid, yield: 81%. 1H NMR (CD3OD, 400 MHz) δ: 8.36 (s, 1H), 8.17 (d, J = 3.3, 1H), 7.96 (dd, J = 7.8, 1.7, 1H), 7.70 (dd, J = 11.7, 4.6, 2H), 7.58–7.48 (m, 1H), 7.44 (t, J = 7.9, 1H), 7.32–7.25 (m, 4H), 7.18 (t, J = 7.1, 2H), 7.08 (t, J = 7.5, 1H), 4.89–4.81 (m, 2H), 4.01 (s, 3H), 3.38 (d, J = 5.1, 1H), 3.25 (dd, J = 13.8, 7.6, 1H), 1.91–1.75 (m, 2H), 1.24 (dd, J = 13.3, 6.1, 1H), 1.06 (d, J = 5.8, 6H);13C NMR (CD3OD, 100 MHz) δ: 20.9, 22.1, 24.9, 36.9, 41.4, 53.1, 55.3, 111.6, 117.6, 120.6, 121.0, 121.9, 122.1, 123.7, 126.5, 128.1, 129.0, 129.4, 130.8, 133.1, 133.2, 136.6, 139.1, 149.6, 157.8, 166.4, 168.0, 172.1; HRMS calcd for C33H34N4O6S [M+H]+ 615.2277, found 615.2281.

(S)-Methyl 2-(3-aminobenzamido)-3-phenylpropanoate (4)

Step 1: To a solution of 3 nitrobenzoic acid (16.71 g, 100 mmol) in 200 mL DCM, was added SOCl2 (14 mL, 200 mmol) and 0.5 mL DMF at room temperature. The reaction mixture was allowed to stir at reflux condition for 5 h. The excess solvent was removed under reduced pressure, the residue was diluted with DCM 50 mL, and added via an additional funnel to a solution of l-Phe-OMe (17.91 g, 100 mmol), Et3N (30.6 g, 300 mmol) in DCM 100 mL at 0 °C. The reaction mixture was allowed to stir at 0 °C for 0.5 h, and then room temperature for 1 h till TLC showed that the reaction completed. Water 200 mL was added to the reaction mixture, the aqueous was extracted with DCM (150 mL × 3). The organic layers were combined, dried, filtered, and concentrated. The residue was re-crystallized from a co-solvent of ethyl acetate and methanol (1:6) to afford a white solid 29.19 g (yield 89%) and used in next step directly. Step 2: To a solution of above compound (29.15 g, 88.9 mmol) in 200 mL methanol, was added 1 g Pd/C (10%). The reaction mixture was allowed to stir under H2 (0.3 MPa) condition at 35 °C for 7 h. The reaction mixture was filtered through a pad of Celite, the filtration was concentrated to afford a gray solid 27.77 g as crude product, which was purified via re-crystallization from methanol and ethyl acetate (1:5) 24.77 g (93%). 1H NMR (400 MHz, CDCl3) δ 7.30–7.33 (m, 4H), 7.17–7.22 (m, 4H), 7.13–7.15 (m,1H), 6.89 (m, 1H), 6.38 (m, 1H), 5.10–5.12 (m, 1H), 3.80 (s, 3H), 3.31 (dd, J = 14.0, 5.8 Hz, 1H), 3.24 (dd, J = 14.0, 5.9 Hz, 1H). 13C NMR (CDCl3, 100 MHz) δ: 37.9, 52.4, 53.5, 113.9, 116.7, 118.3, 127.2, 128.6, 129.3, 135.0, 135.5, 135.8, 146.5, 167.0, 172.0; HRMS calcd for C17H18N2O3 [M+H]+ 299.1317, found 299.1314.

(S)-Methyl 2-(5-amino-2-bromobenzamido)-3-phenylpropanoate (4a)

Made by the same method as described in compound 4. 1H NMR (400 MHz, CDCl3) δ 7.30–7.34 (m, 6H), 7.21–7.26 (m, 1H), 6.68 (s, 1H), 6.61–6.65 (m, 2H), 5.09–5.13 (m, 1H), 3.81 (s, 3H), 3.22–3.36 (m, 2H). 13C NMR (CDCl3, 100 MHz) δ: 37.8, 51.8, 53.7, 116.0, 117.9, 122.0, 127.2, 128.6, 129.4, 133.8, 134.2, 167.0, 146.6, 166.5, 171.2; HRMS calcd for C17H17BrN2O3 [M+H]+ 377.0423, found 377.0418.

(S)-Methyl 2-(3-((S)-2-(9 (tert-butoxycarbonyl)amino)-3-methylbutanamido)benzamido)-3-phenylpropanoate (5)

To a solution of Boc-l-Val (8.68 g, 40.0 mmol) in 60 mL DCM, was added EDC (9.98 g, 52.0 mmol), HOBt (5.40 g, 40.0 mmol), and 3 mL DIPEA at 0 °C. The reaction mixture was allowed to stir room temperature for 1 h. Then a solution of compound 6 (11.92 g, 40.0 mmol) in DCM was added to above reaction mixture. The resulting reaction mixture was stirred at room temperature for 1 h. Water 150 mL was added, and the aqueous layer was extracted with DCM (120 mL × 3). The organic layers were combined, dried, filtered, and concentrated. The residue was purified by a chromatography (EA: PE = 1:4) to afford white solid 16.70 g (yield: 84%). 1H NMR (400 MHz, CDCl3) δ 9.18 (s, 1H), 7.63–7.71 (m, 2H), 7.18–7.34 (m, 6H), 7.08 (m, 1H), 6.97 (m, 1H), 5.83–5.86 (m, 1H), 5.18–5.19 (m, 1H), 4.30–4.34 (m,1H), 3.78 (s, 3H), 3.26–3.28 (m, 2H), 2.17–2.18 (m, 1H), 1.56 (s, 9H), 1.04–1.14 (m, 6H). 13C NMR (100 MHz, CDCl3) δ: 19.2, 28.3, 31.0, 38.1, 52.3, 53.7, 60.9, 80.7, 117.3, 122.1, 123.0, 126.9, 128.5, 128.9, 129.3, 134.8, 136.5, 137.3, 167.3, 168.3, 171.4, 172.7; HRMS calcd. for C27H35N3O6[M+H]+ Exact Mass: 498.2526, found 498.2538.

(S)-Methyl2-(2-bromo-5-((S)-2-(tert-butoxycarbonyl)-3-methylbutanamido)benzamido)-3-phenylpropanoate (5a)

Made by the same method as described in compound 5. 1H NMR (CDCl3, 400 MHz) δ: 9.17 (br s, 1H), 7.74 (m, 1H), 7.49–7.51 (m, 1H), 7.30–7.32 (m, 5H), 7.12–7.14 (m, 1H), 6.81 (br s, 1H), 6.01 (m, 1H), 5.15–5.21 (m, 1H), 4.28 (m, 1H), 3.81 (s, 3H), 3.25–3.35 (m, 2H), 2.07–2.17 (m, 1H), 1.47 (s, 9H), 1.06–1.11 (m, 6H). 13C NMR (CDCl3, 100 MHz) δ: 19.1, 28.3, 29.7, 38.2, 52.3, 53.6, 60.7, 82.1, 113.9, 117.4, 118.9, 121.1, 127.0, 128.5, 129.4, 133.8, 136.1, 136.7, 157.3, 165.3, 166.6, 172.3. HRMS calcd for C27H34BrN3O6 [M+H]+ 576.1631, found 576.1628.

(S)-methyl 2-(3-((S)-2-((S)-2-((tert-butoxycarbonyl)amino)-4-methylpentanamido)-3-methylbutanamido)benzamido)-3-phenylpropanoate (6)

To a solution of Boc-l-Leu (4.50 g, 19.5 mmol) in 50 mL DCM, was added EDC (4.87 g, 25.4 mmol), HOBt (2.63 g, 19.5 mmol), and 1 mL DIPEA at 0 °C. The reaction mixture was stirred at room temperature for 1 h. Meanwhile, a solution of compound 7 (9.69 g, 19.5 mmol) in 4 mL TFA was stirred for 3 h at room temperature. The access of TFA was removed under reduced pressure. The residue was diluted in 25 mL DCM, and added to above reaction mixture via an additional funnel. The resulting reaction mixture was allowed to stir at room temperature overnight. Water 100 mL was added, and the aqueous layer was extracted with DCM (100 mL × 3). The organic layers were combined, dried, filtered, and concentrated. The residue was purified by a chromatography (EA:PE = 1:3) to afford compound 6 as white solid 9.89 g (yield 83%). 1H NMR (400 MHz, CDCl3) δ: 9.42 (s, 1H), 8.00 (d, J = 7.7, 1H), 7.92 (s, 1H), 7.30 (dd, J = 14.6, 7.6, 4H), 7.25 (d, J = 7.2, 1H), 7.16 (d, J = 6.9, 2H), 6.91 (d, J = 7.2, 1H), 6.85 (d, J = 7.6, 1 H), 5.74 (s, 1H), 5.06 (dd, J = 13.4, 6.0, 1H), 4.67–4.37 (m, 1H), 4.15 (s, 1H), 3.73 (s, 3H), 3.25 (qd, J = 13.9, 5.9, 2H), 2.25 (d, J = 6.3, 1H), 1.74 (dd, J = 13.3, 6.6, 1H), 1.62 (dd, J = 9.4, 4.9, 2 H), 1.37 (s, 9H), 1.00 (d, J = 6.7, 6H), 0.91 (d, J = 6.5, 6H).

13C NMR (CDCl3, 100 MHz) δ:17.3, 22.2, 22.6, 28.3, 31.1, 37.1, 41.2, 51.9, 52.6, 53.6, 58.6, 79.9, 117.7, 122.1, 123.1, 126.9, 127.9, 128.9, 129.2, 134.9, 138.7, 139.6, 156.1, 167.7, 171.3, 171.6, 172.1. HRMS calcd for C33H46N4O7 [M+H]+ 611.3366, found 611.3358.

(S)-Methyl2-(2-bromo-5-((S)-2-((S)-2-(tert-butoxycarbonyl)-4-methylpentanamido)-3-methylbutanamido)benzamido)-3-phenylpropanoate (6a)

Made by the same method as described in compound 6. 1H NMR (CDCl3, 400 MHz) δ: 9.32 (br s, 1H), 7.89–7.99 (m, 1H), 7.82 (m, 1H), 7.26–7.31 (m, 4H), 7.15–7.17 (m, 2H), 6.84–6.86 (m, 2H), 5.75 (br s, 1H), 4.94–4.98 (m, 1H), 4.56–4.60 (m, 1H), 4.15 (m, 1H), 3.75 (s, 3H), 3.17–3.29 (m, 2H), 2.23–2.25 (m, 1H), 1.74–1.77 (m, 1H), 1.60–1.63 (m, 2H), 1.37 (s, 9H), 0.90–1.01 (d, J = 8.0, 12H). 13C NMR (CDCl3, 100 MHz) δ:17.3, 22.2, 22.5, 28.3, 31.0, 37.1, 41.2, 51.9, 52.7, 53.6, 58.9, 79.7, 118.9, 122.1, 123.0, 126.9, 128.6, 128.9, 129.3, 134.9, 137.7, 139.2, 156.5, 167.7, 171.2, 171.5, 172.3. HRMS calcd for C33H45BrN4O7 [M+H]+ 689.2472, found 689.2481.

Compounds IIa–IIg were synthesized by the same method as described in compound Ia.

IIa: white solid, yield 80%. 1H NMR (CD3OD, 400 MHz) δ: 7.98 (d, J = 8.8, 1H), 7.72 (dd, J = 8.0, 7.1, 1H), 7.45 (dd, J = 7.7, 1.3, 1H), 7.36 (td, J = 7.9, 1.6, 1H), 7.31–7.19 (m, 4 H), 7.15 (td, J = 7.1, 1.5, 1H), 4.78–4.63 (m, 1H), 4.53–4.40 (m, 1H), 4.36 (d, J = 7.6, 1H), 3.35–3.29 (m, 2H), 2.52 (d, J = 2.9, 1H), 2.45 (d, J = 2.7, 3H), 2.15 (dd, J = 13.9, 6.9, 1H), 1.94 (d, J = 8.1, 1H), 1.81 (d, J = 13.0, 1H), 1.68 (tdd, J = 15.2, 10.9, 4.5, 6H), 0.95 (ddd, J = 11.5, 8.5, 4.5, 12H); 13C NMR (CD3OD, 100 MHz) δ: 17.2, 18.4, 20.3, 20.9, 22.0, 24.6, 29.2, 30.5, 39.9, 42.5, 46.3, 52.0, 54.9, 59.2, 67.8, 118.7, 122.4, 122.6, 125.6, 125.9, 127.7, 128.6, 129.1, 135.3, 138.0, 170.0, 170.6, 171.9, 172.1, 173.2; HRMS calcd for C34H47N5O6 [M+H]+ 622.3605, found 622.3599.

IIb: white solid, yield 79%.1H NMR (CD3OD, 400 MHz) δ: 7.95 (d, J = 12.5, 1H), 7.68 (dd, J = 19.6, 8.2, 1H), 7.45 (d, J = 7.9, 1H), 7.37 (t, J = 7.9, 1H), 7.24 (q, J = 7.2, 3H), 7.15 (t, J = 6.6, 1H), 4.60–4.47 (m, 1H), 4.48–4.37 (m, 1H), 4.38–4.26 (m, 1H), 3.50 (d, J = 9.6, 1H), 3.13 (s, 1H), 2.94–2.72 (m, 1H), 2.15 (ddd, J = 40.8, 24.7, 14.9, 2H), 1.86 (dd, J = 26.9, 15.5, 2H), 1.69 (dt, J = 13.8, 9.6, 4H), 1.10–0.84 (m, 12H). 13C NMR (CD3OD, 100 MHz) δ: 17.2, 18.4, 20.2, 21.1, 22.0, 24.6, 29.3, 30.9, 40.1, 42.5, 45.9, 52.1, 55.0, 59.2, 67.8, 118.8, 122.4, 122.7, 125.6, 125.9, 127.7, 128.6, 129.3, 135.4, 138.0, 170.1, 170.3, 171.9, 174.4, 174.9. HRMS calcd for C34H47N5O6 [M+H]+ 622.3605, found 622.3599.

IIc: white solid, yield 80%.1H NMR (CD3OD, 400 MHz) δ: 8.63 (t, J = 1.9, 1H), 8.33–8.25 (m, 1 H), 8.15 (d, J = 7.8, 1H), 7.63 (d, J = 8.0, 1H), 7.61–7.54 (m, 1H), 7.34 (d, J = 7.8, 1H), 7.27 (t, J = 7.9, 1H), 7.22 –7.13 (m, 4H), 7.12–7.05 (m, 1H), 4.73 (dd, J = 9.5, 4.9, 3H), 4.65 (dd, J = 9.4, 4.3, 1H), 4.26 (t, J = 6.6, 1H), 3.30 (s, 1H), 3.13–2.93 (m, 1H), 2.07 (dd, J = 13.2, 6.7, 1H), 1.64 (ddd, J = 26.5, 10.3, 5.4, 3H), 0.99–0.81 (m, 12H); 13C NMR (CD3OD, 100 MHz) δ: 20.5, 22.0, 24.8, 30.9, 36.8, 40.1, 52.7, 54.3, 59.5, 118.9, 122.1, 122.7, 123.0, 125.8, 126.3, 128.1, 128.6, 128.8, 129.6, 133.2, 134.8, 135.5, 137.2, 138.1, 148.2, 166.5, 168.5, 170.9, 173.4, 173.6; HRMS calcd for C34H39N4O8 [M+H]+ 646.2877, found 646.2880.

IId: white solid, yield 78%. 1H NMR (CD3OD, 400 MHz) δ: 7.92–7.83 (m, 1H), 7.76 (d, J = 7.4, 2H), 7.57 (d, J = 5.3, 1H), 7.43 (s, 1H), 7.34 (dd, J = 14.3, 7.0, 3H), 7.23 (t, J = 7.8, 1H), 7.14 (dd, J = 14.2, 7.4, 4H), 7.03 (t, J = 7.0, 1H), 4.63 (d, J = 9.8, 2H), 4.27 (d, J = 7.4, 1H), 3.61 (dq, J = 13.2, 6.6, 4H), 3.00 (dd, J = 13.7, 8.3, 1H), 2.06 (dd, J = 13.6, 6.8, 1H), 1.76–1.52 (m, 3H), 0.95–0.81 (m, 12H). 13C NMR (CD3OD, 100 MHz) δ: 17.3, 17.9, 18.1, 18.4, 30.5, 37.8, 55.6, 58.9, 59.4, 117.1, 125.8, 127.0, 127.6, 128.1, 128.8, 129.3, 131.3, 134.1, 134.7, 135.7, 137.6, 143.6, 144.3, 161.0, 169.0, 170.5, 171.3, 172.8; HRMS calcd for C34H40N4O6 [M+H]+ 601.3026, found 601.3029.

IIe: white solid, yield 82%.1H NMR (CD3OD, 400 MHz) δ: 8.06 (d, J = 6.2, 1H), 8.03–7.95 (m, 1H), 7.85–7.77 (m, 1H), 7.66–7.59 (m, 1H), 7.56 (d, J = 7.8, 1H), 7.49 (t, J = 7.8, 1H), 7.44–7.34 (m, 4H), 7.34–7.24 (m, 2H), 7.17 (t, J = 7.5, 1H), 4.93 (dd, J = 9.3, 4.6, 1H), 4.86 (t, J = 7.1, 1H), 4.46 (d, J = 7.5, 1H), 4.10 (s, 3H), 3.47 (d, J = 4.8, 1H), 3.22 (dd, J = 13.8, 9.4, 1H), 2.34–2.24 (m, 1H), 1.89–1.77 (m, 3H), 1.13 (ddd, J = 18.5, 8.7, 4.4, 12H); 13C NMR (CD3OD, 100 MHz) δ: 19.3, 20.7, 22.0, 24.7, 30.8, 36.8, 40.8, 52.3, 55.1, 59.3, 111.5, 118.9, 120.5, 121.1, 122.7, 123.0, 126.3, 128.0, 128.6, 128.9, 130.6, 132.9, 134.9, 137.4, 138.2, 139.5, 157.6, 166.7, 170.7, 171.5, 173.5; HRMS calcd for C35H42N4O7 [M+H]+ 631.3132, found 631.3136.

IIf: white solid, yield 78%. 1H NMR (400 MHz, MeOD) δ 7.73 (s, 1H), 7.39–7.41 (d, J = 8.6 Hz, 1H), 7.32–7.33 (m, 2H), 7.14–7.22 (m, 3H), 6.98–7.02 (m, 1H), 4.63–4.66 (dd, J = 9.5, 4.0 Hz, 1H), 4.22–4.34 (m, 2H), 3.20–3.21 (m, 4H), 2.80–2.83 (m, 1H), 2.47–2.72 (m, 1H), 2.56 (s, 3H), 2.15–2.17 (m, 1H), 1.39–1.76 (m, 8H), 0.71–0.97 (m, 12H); 13C NMR (CD3OD, 100 MHz) δ:17.2, 18.3, 20.2, 21.9, 23.7, 24.6, 29.2, 30.4, 39.9, 42.5, 51.9, 54.9, 59.2, 67.8, 117.6, 122.5, 122.6, 125.9, 127.7, 128.6, 129.1, 135.3, 138.0, 139.7, 170.0, 170.6, 171.9, 172.1, 173.2; HRMS calcd for C34H46BrN5O6 [M+H]+ 700.2631, found 700.2636.

IIg: white solid, yield 72%. 1H NMR (400 MHz, MeOD) δ 7.99 (s, 1H), 7.72–7.74 (d, J = 8.6 Hz, 1H), 7.44–7.46 (m, 2H), 7.36–7.38 (m, 2H), 7.15–7.17 (m, 2H), 4.69–4.71 (m, 1H), 4.44–4.47 (m, 1H), 4.35–4.37 (m, 1H),3.73–3.75 (m, 1H), 3.32–3.35 (m, 1H),3.20–3.24 (m, 1H), 2.45–2.52 (m, 1H), 2.44 (s, 3H), 2.16–2.18 (m, 1H), 1.62–1.80 (m, 8H), 1.36–1.37 (m, 2H), 0.91–1.20 (m, 12H); 13C NMR (CD3OD, 100 MHz) δ: 17.3, 18.4, 20.3, 20.9, 21.8, 23.7, 24.6, 29.3, 30.5, 39.9, 42.5, 51.9, 54.9, 59.3, 65.8, 117.8, 122.5, 122.6, 125.9, 127.7, 128.7, 129.1, 135.3, 138.0, 139.7, 170.0, 170.6, 171.9, 172.1, 173.0; HRMS calcd for C34H46BrN5O6 [M+H]+ 700.2631, found 700.2634.

Abbreviations

EDC: 

1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride

TFA: 

trifluoroacetic acid

DIPEA: 

N,N-diisopropylethylamine

HOBt: 

1-hydroxybenzotriazole

DCM: 

dichloromethane

Boc-l-Val: 

N-Boc-l-Valine

Boc-l-Leu: 

N-Boc-l-Leucine

l-Phe-OEt: 

l-phenylalanine ethyl ester

DMF: 

N,N-dimethylformamide

Declarations

Authors’ contributions

The main part of the work was carried out by SM, with the direct supervision of LY. Conceptually the work was designed by XB, XM and NY. All authors read and approved the final manuscript.

Acknowledgements

The authors would like to thank Dr. Hongbo Wang for his very helpful discussions concerning the pharmacological test.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

Not applicable.

Consent for publication

All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Funding

Doctor Foundation of Yantai University (YX13B04) and the Shandong Blue Economic Zone Talent Development Project (RS11YX).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, 264005, People’s Republic of China

References

  1. Sasse F, Sieinmetz H, Heil J, Höfle G, Reichenbach H (2000) Tubulysins, new cytostatic peptides from myxobacteria acting on microtubuli. Production, isolation, physico-chemical and biological properties. J Antibiot 53:879–885View ArticleGoogle Scholar
  2. Steinmetz H, Glaser N, Herdtweck E, Sasse F, Reichenbach H, Höfle G (2004) Isolation, crystal and solution structure determination, and biosynthesis of tubulysins—powerful inhibitors of tubulin polymerization from myxobacteria. Angew Chem Int Ed 43:4888–4892View ArticleGoogle Scholar
  3. Peltier HM, McMahon JP, Patterson AW, Ellman JA (2006) The total synthesis of tubulysin D. J Am Chem Soc 128:16018–16019View ArticleGoogle Scholar
  4. Sani M, Fossati G, Huguenot F, Zanda M (2007) Total synthesis of tubulysins U and V. Angew Chem 119:3596–3599View ArticleGoogle Scholar
  5. Pando O, Dörner S, Preusentanz R, Denkert A, Porzel A, Richter W, Wessjohann L (2009) First total synthesis of tubulysin B. Org Lett 11:5567–5569View ArticleGoogle Scholar
  6. Ullrich A, Chai Y, Pistorius D, Elnakady YA, Herrmann JE, Weissman KJ, Kazmaier U, Müller R (2009) Pretubulysin, a potent and chemically accessible tubulysin precursor from Angiococcus disciformis. Angew Chem Int Ed 48:4422–4425View ArticleGoogle Scholar
  7. Braig S, Wiedmann RM, Liebl J, Singer M, Kubisch R, Schreiner L, Abhari BA, Wagner E, Kazmaier U, Fulda S, Vollmar AM (2014) Pretubulysin: a new option for the treatment of metastatic cancer. Cell Death Dis 5:e1001View ArticleGoogle Scholar
  8. Kubisch R, von Gamm M, Braig S, Ullrich A, Burkhart JL, Colling L, Hermann J, Scherer O, Müller R, Werz O, Kazmaier U (2014) Simplified pretubulysin derivatives and their biological effects on cancer cells. J Nat Prod 77:536–542View ArticleGoogle Scholar
  9. Burkhart JL, Műller R, Kazmaier U (2011) Syntheses and evaluation of simplified pretubulysin analogues. Eur J Org Chem 16:3050–3059View ArticleGoogle Scholar
  10. Murray BC, Peterson MT, Fecik RA (2015) Chemistry and biology of tubulysins: antimitotic tetrapeptides with activity against drug resistant cancers. Nat Prod Rep 32:654–662View ArticleGoogle Scholar
  11. Xu XM, Gregory KF, Yao L (2013) Recent advances in the synthesis of tubulysins. Mini-Rev Med Chem 13:1572–1578View ArticleGoogle Scholar
  12. Park Y, Bae SY, Hah JM, Lee SK, Ryu JS (2015) Synthesis of stereochemically diverse cyclic analogs of tubulysins. Bioorg Med Chem 23:6827–6843View ArticleGoogle Scholar
  13. Park Y, Lee JK, Ryu JS (2015) Synthesis of a cyclic analogue of Tuv N-methyl tubulysin. Synlett 26:1063–1068View ArticleGoogle Scholar
  14. Shibue T, Hirai T, Okamoto I, Morita N, Masu H, Azumaya I, Tamura O (2010) Total syntheses of tubulysins. Chem Eur J 16:11678–11688View ArticleGoogle Scholar
  15. Ullrich A, Herrman J, Müller R, Kazmaier U (2009) Synthesis and biological evaluation of pretubulysin and derivatives. Eur J Org Chem 36:6367–6378View ArticleGoogle Scholar

Copyright

© The Author(s) 2018

Advertisement

BMC Chemistry

ISSN: 2661-801X

Contact us